{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T05:12:20Z","timestamp":1785388340486,"version":"3.55.0"},"reference-count":29,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2023,12,30]],"date-time":"2023-12-30T00:00:00Z","timestamp":1703894400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: Uterine leiomyosarcoma (uLMS) is characterized by aggressive behavior associated with a high risk of relapse and mortality. Several therapeutic agents have been employed in the treatment of metastatic disease, with a poor objective response rate. Pazopanib, approved in 2012, is a multi-targeted, orally active small molecule that exerts its effects by inhibiting several tyrosine kinases. To date, poor research on real-life data has been conducted. We aimed to assess the effectiveness and safety of the drug in everyday clinical practice. Methods: We present results of multicenter retrospective data on 38 patients with heavily pretreated metastatic uLMS who underwent oral pazopanib during their therapeutic journey. Results: At a median follow-up of 8.6 months, the disease control rate was 55.2%, with 17% partial responses and 15 patients (39.5%) with stable disease. At a median follow-up of 8.6 months, median progression-free survival was 4 months, and median overall survival was 19.8 months. The most common grade 3 adverse events (AEs) drug-related were hepatic toxicities, diarrhea, hypertension, nausea, and vomiting (all of them with an incidence of 5% considering the whole study cohort). No grade 4 AEs occurred. Conclusions: Pazopanib in everyday clinical practice is safe and shows a good disease control rate with prolonged survival.<\/jats:p>","DOI":"10.3390\/cancers16010192","type":"journal-article","created":{"date-parts":[[2023,12,31]],"date-time":"2023-12-31T04:51:51Z","timestamp":1703998311000},"page":"192","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["A Ten-Year Real-Life Experience with Pazopanib in Uterine Leyomiosarcoma in Two High-Specialized Centers in Italy: Effectiveness and Safety"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1016-4995","authenticated-orcid":false,"given":"Mara","family":"Mantiero","sequence":"first","affiliation":[{"name":"Department of Gynecologic Oncology, National Cancer Institute of Milan, Via Venezian 1, 20133 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Bini","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, National Cancer Institute of Milan, Via Venezian 1, 20133 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maggie","family":"Polignano","sequence":"additional","affiliation":[{"name":"Department of Gynecologic Oncology, National Cancer Institute of Milan, Via Venezian 1, 20133 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Porcu","sequence":"additional","affiliation":[{"name":"Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge CB2 0RE, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Sanfilippo","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, National Cancer Institute of Milan, Via Venezian 1, 20133 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Fabbroni","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, National Cancer Institute of Milan, Via Venezian 1, 20133 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Parma","sequence":"additional","affiliation":[{"name":"Gynecologic Oncology Division, European Institute of Oncology, Via Giuseppe Ripamonti, 435, 20141 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariateresa","family":"Lapresa","sequence":"additional","affiliation":[{"name":"Gynecologic Oncology Division, European Institute of Oncology, Via Giuseppe Ripamonti, 435, 20141 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmelo","family":"Calidona","sequence":"additional","affiliation":[{"name":"Gynecologic Oncology Division, European Institute of Oncology, Via Giuseppe Ripamonti, 435, 20141 Milan, Italy"},{"name":"Department of Obstetrics and Gynecology, AOUI Verona, University of Verona, Piazzale Aristide Stefani 1, 37126 Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Silvestri","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, National Cancer Institute of Milan, Via Venezian 1, 20133 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Franza","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, National Cancer Institute of Milan, Via Venezian 1, 20133 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Raspagliesi","sequence":"additional","affiliation":[{"name":"Department of Gynecologic Oncology, National Cancer Institute of Milan, Via Venezian 1, 20133 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicoletta","family":"Colombo","sequence":"additional","affiliation":[{"name":"Gynecologic Oncology Division, European Institute of Oncology, Via Giuseppe Ripamonti, 435, 20141 Milan, Italy"},{"name":"University of Milan-Bicocca, Piazza dell\u2019Ateneo Nuovo 1, 20126 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Ducceschi","sequence":"additional","affiliation":[{"name":"Department of Gynecologic Oncology, National Cancer Institute of Milan, Via Venezian 1, 20133 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,12,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.ejca.2020.08.016","article-title":"Italian consensus conference on management of uterine sarcomas on behalf of S.I.G.O. (Societa\u2019 italiana di Ginecologia E Ostetricia)","volume":"139","author":"Ferrandina","year":"2020","journal-title":"Eur. J. Cancer"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ygyno.2009.09.023","article-title":"Uterine sarcomas: A review","volume":"116","author":"Prat","year":"2010","journal-title":"Gynecol. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.ygyno.2018.09.010","article-title":"Uterine leiomyosarcoma: A review of the literature and update on management options","volume":"151","author":"Roberts","year":"2018","journal-title":"Gynecol. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ijgo.2008.12.008","article-title":"FIGO staging for uterine sarcomas","volume":"104","author":"Prat","year":"2009","journal-title":"Int. J. Gynaecol. Obstet."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/S0090-8258(03)00137-9","article-title":"Retrospective review of 208 patients with leiomyosarcoma of the uterus: Prognostic indicators, surgical management, and adjuvant therapy","volume":"89","author":"Giuntoli","year":"2003","journal-title":"Gynecol. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.critrevonc.2017.12.009","article-title":"Systemic treatment in adult uterine sarcomas","volume":"122","author":"Desar","year":"2018","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/S1470-2045(17)30622-8","article-title":"Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): A randomised controlled phase 3 trial","volume":"18","author":"Seddon","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.ygyno.2004.11.036","article-title":"Phase II evaluation of liposomal doxorubicin (Doxil) in recurrent or advanced leiomyosarcoma of the uterus: A Gynecologic Oncology Group study","volume":"96","author":"Sutton","year":"2005","journal-title":"Gynecol. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1006\/gyno.1996.0220","article-title":"Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcomas of the uterus: A Gynecologic Oncology Group study","volume":"62","author":"Sutton","year":"1996","journal-title":"Gynecol. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1200\/JCO.2015.62.4734","article-title":"Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: Results of a phase III randomized multicenter clinical trial","volume":"34","author":"Demetri","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Asano, H., Isoe, T., Ito, Y.M., Nishimoto, N., Watanabe, Y., Yokoshiki, S., and Watari, H. (2022). Status of the Current Treatment Options and Potential Future Targets in Uterine Leiomyosarcoma: A Review. Cancers, 14.","DOI":"10.3390\/cancers14051180"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Maccaroni, E., Lunerti, V., Agostinelli, V., Giampieri, R., Zepponi, L., Pagliacci, A., and Berardi, R. (2022). New Insights into Hormonal Therapies in Uterine Sarcomas. Cancers, 14.","DOI":"10.3390\/cancers14040921"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1093\/jjco\/hyy053","article-title":"Drug review: Pazopanib","volume":"48","author":"Miyamoto","year":"2018","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1016\/S0140-6736(12)60651-5","article-title":"Pazopanib for metastatic soft-tissue sarcoma (PALETTE): A randomised, double-blind, placebo-controlled phase 3 trial","volume":"379","author":"Blay","year":"2012","journal-title":"Lancet"},{"key":"ref_15","first-page":"2327","article-title":"Efficacy of Pazopanib in patients with metastatic uterine sarcoma: A multi-institutional study","volume":"24","author":"Sunar","year":"2019","journal-title":"J. Buon"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.3802\/jgo.2018.29.e3","article-title":"Pazopanib monotherapy in the treatment of pretreated, metastatic uterine sarcoma: A single-center retrospective study","volume":"29","author":"Kim","year":"2018","journal-title":"J. Gynecol. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1080\/0284186X.2017.1332779","article-title":"Treatment patterns and clinical outcomes with pazopanib in patients with advanced soft tissue sarcomas in a compassionate use setting: Results of the SPIRE study","volume":"56","author":"Gelderblom","year":"2017","journal-title":"Acta Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Cesne, A.L., Bauer, S., Demetri, G.D., Han, G., Dezzani, L., Ahmad, Q., Blay, J.Y., Judson, I., Sch\u00f6ffski, P., and Aglietta, M. (2019). Safety and efficacy of Pazopanib in advanced soft tissue sarcoma: PALETTE (EORTC 62072) subgroup analyses. BMC Cancer, 19.","DOI":"10.1186\/s12885-019-5988-3"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ygyno.2016.03.024","article-title":"Outcome of uterine sarcoma patients treated with pazopanib: A retrospective analysis based on two European Organisation for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group (STBSG) clinical trials 62043 and 62072","volume":"142","author":"Benson","year":"2016","journal-title":"Gynecol. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1093\/jjco\/hyv022","article-title":"Differences in the responses to pazopanib and the prognoses of soft tissue sarcomas by their histological eligibility for the PALETTE study","volume":"45","author":"Nakano","year":"2015","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1586\/era.12.41","article-title":"Pazopanib in the treatment of soft tissue sarcoma","volume":"12","year":"2012","journal-title":"Expert. Rev. Anticancer Ther."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/CCO.0b013e3283622d3a","article-title":"Pazopanib in sarcomas: Expanding the PALETTE","volume":"25","author":"Wilky","year":"2013","journal-title":"Curr. Opin. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3154","DOI":"10.1200\/JCO.2008.20.9890","article-title":"Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas","volume":"27","author":"George","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.ygyno.2009.09.011","article-title":"Sunitinib malate in the treatment of recurrent or persistent uterine leiomyosarcoma: A Gynecologic Oncology Group phase II study","volume":"115","author":"Hensley","year":"2009","journal-title":"Gynecol. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1200\/JCO.2014.58.3781","article-title":"Randomized phase III trial of gemcitabine plus docetaxel plus bevacizumab or placebo as first-line treatment for metastatic uterine leiomyosarcoma: An NRG Oncology\/Gynecologic Oncology Group study","volume":"33","author":"Hensley","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"Abst 11007","DOI":"10.1200\/JCO.2017.35.15_suppl.11007","article-title":"A multicenter phase II study of nivolumab +\/\u2212 ipilimumab for patients with metastatic sarcomas (alliance A091401)","volume":"35","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/S1470-2045(17)30624-1","article-title":"Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): A multicentre, two-cohort, single-arm, open-label, phase 2 trial","volume":"18","author":"Tawbi","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41392-019-0049-6","article-title":"Pazopanib in advanced soft tissue sarcomas","volume":"4","author":"Lee","year":"2019","journal-title":"Signal. Transduct. Target. Ther."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Cope, B.M., Traweek, R.S., Lazcano, R., Keung, E.Z., Lazar, A.J., Roland, C.L., and Nassif, E.F. (2023). Targeting the Molecular and Immunologic Features of Leiomyosarcoma. Cancers, 15.","DOI":"10.3390\/cancers15072099"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/1\/192\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:44:53Z","timestamp":1760132693000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/1\/192"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,30]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1]]}},"alternative-id":["cancers16010192"],"URL":"https:\/\/doi.org\/10.3390\/cancers16010192","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,30]]}}}